The DOI matches its Crossref record.
Evolution of the market for mRNA technology
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mRNA-5671/V941 is currently in Phase I clinical trials against KRAS-mutant NSCLC, PDAC, and CRC [84].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [84]
Citations
Cites
Still being checked.
Cited by
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Next, we discuss the methods and strategies cancers employ to resist KRAS inhibition.”
Method
Metadata
- Authors
- Xie, W., Chen, B., & Wong, J.
- Affiliations
- Boston Consulting Group (United States) (US)
- Corresponding author
- Wong, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2021-09-02
- Volume
- 20
- Issue
- 10
- Pages
- 735-736
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W3196420132
- Cited by
- 42
- References
- 0
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 15 · 2023: 10 · 2022: 5 · 2021: 1
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-10-04)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- mRNA technology, mRNA therapeutics, market development, biotechnology industry, drug development
- MeSH terms
- Genetic Techniques, Humans, RNA, Messenger, Vaccines, Health Care Sector
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of the market for mRNA technology. https://app.cochat.ai/papers/10.1038/d41573-021-00147-y
- The paper
- Xie, W., Chen, B., & Wong, J. (2021). Evolution of the market for mRNA technology. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-021-00147-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.